Skip to content

Daily versus as-needed use of fluticasone furoate nasal spray in patients with allergic rhinitis: A randomized controlled trial

Daily versus as-needed use of fluticasone furoate nasal spray in patients with allergic rhinitis: A randomized controlled trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20170310002
Enrollment
Unknown
Registered
2017-03-10
Start date
2017-10-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

moderate&#45

Interventions

Fluticason furoate nasal spray 2 puffs/nostril/day for consecutive 6 weeks,Fluticason furoate nasal spray 2 puffs/nostril/day for consecutive 1 week followed by as&#45
needed use adjusted by patient (not exceed 2 puffs/nostril/day) for 5 weeks
Experimental Drug,Experimental Drug
Daily FF,As&#45
needed FF

Sponsors

Siriraj research development fund, Faculty of medicine Siriraj hospital, Mahidol university
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. physician-diagnosed of moderate-severe persistent allergic rhinitis for at least 1 year duration with TNSS (Total nasal symptoms score) equal or greater than 6 2. Recent skin prick test result within 1 year which shown positive for at least 1 aeroallergen

Exclusion criteria

Exclusion criteria: 1. Patients who were pregnant or in lactating period 2. Recent use of oral or topical decongestant within 7 days, intranasal steroid within 4 weeks, systemic corticosteroid within 8 weeks, H1-antihistamine or anti-leukotriene within 2 weeks and systemic corticosteroid within 8 weeks 3. Concurrent diseases such as asthma, urticaria and atopic dermatitis 4. Patients who were currently or previously treated with immunotherapy 5. Patients who were diagnosed with upper respiratory tract infection within the previous 14 days 6. Patients with rhinosinusitis, nasal polyps or significant deviated nasal septum. 7. Patients with a history of asthma, chronic lung diseases, cardiovascular, hepatic, or renal diseases

Design outcomes

Primary

MeasureTime frame
Effectiveness of daily versus as-needed use of fluticasone furoate nasal spray 6 weeks Total nasal symptom score

Secondary

MeasureTime frame
Accumulation dose of daily versus as-needed fluticasone furoate nasal spray 6 weeks Accumulative dose of fluticasone furoate,Effectiveness of fluticasone furoate nasal spray within each group 6 weeks Total nasal symptom score,Nasal peak inspiratory flow rate between of daily versus as-needed fluticasone furoate group 6 weeks NPIF,Quality of life of daily of daily versus as-needed fluticasone furoate group 6 weeks RCQ-36 score

Contacts

Public ContactMongkhon Sompornrattanaphan

Department of medicine Siriraj hospital, Mahidol university

mongkhon.som@mahidol.ac.th66814514774

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026